Literature DB >> 15317743

In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.

Delphine Croisier1, Manuel Etienne, Lionel Piroth, Emilie Bergoin, Catherine Lequeu, Henri Portier, Pascal Chavanet.   

Abstract

OBJECTIVES: To investigate the impact of low levels of fluoroquinolone resistance on the emergence of resistant mutants, we examined the mutant selection window (MSW) hypothesis in experimental pneumonia in rabbits infected with pneumococci with various susceptibility levels to fluoroquinolones and treated with gatifloxacin using a human-like regimen (equivalent to 400 mg once daily). The MSW corresponds to the range of concentrations between the minimal inhibitory concentration (MIC) and the mutant prevention concentration (MPC), which is the antibiotic concentration that prevents selection of resistant mutants.
MATERIALS AND METHODS: Five pneumococcal strains were tested and were defined as follows [MIC of ciprofloxacin (mg/L)/MIC of gatifloxacin (mg/L)/MPC of gatifloxacin (mg/L)/involved quinolone resistance mechanisms]: strain 16089=0.5/0.25/0.25/wild-type; strain MS1A=2/0.5/1/efflux; strain MS2A=8/1/8/parC S79F; strain MR3B4=10/1/8/parC S79T; strain Gyr-1207=6/4/4/gyrA S81F.
RESULTS: A 48 h human-like treatment with gatifloxacin was significantly bactericidal on pneumonia induced by strain 16089 ( > 6 log(10) killing) as well as the efflux derivative strain MS1A ( > 5 log(10) killing). However, a small number of parC-gyrA mutants were recovered in 26% of the animals infected with this efflux strain. As expected, no decrease in viable bacteria counts was observed when pneumonia was induced by the gyrA resistant strain. In contrast, because of the enrichment of highly resistant mutants in 100% of the animals, no significant bacterial reduction was observed after treatment of pneumonia induced by the two susceptible parC mutated strains. A classification and regression tree (CART) analysis identified T(MSW) (percentage of the time during which gatifloxacin serum concentrations are inside the MSW) and AUC(MSW) (area under curve between MIC and MPC values) as the best parameters associated with the enrichment of resistant pneumococci.
CONCLUSIONS: This study shows that the acquisition of a low level of fluoroquinolone resistance (especially a parC mutation and to a lesser extent an efflux mechanism) is associated with a clearly lower potential for preventing resistance development. These data support the concept that resistant mutants are selectively enriched when antibiotic concentrations fall inside the mutant selection window and suggest that in vivo dynamic models have to be used to predict the relative abilities of quinolones to prevent mutant selection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15317743     DOI: 10.1093/jac/dkh393

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

1.  Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial infection model.

Authors:  Aude A Ferran; Anne-Sylvie Kesteman; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Antimicrob Agents Chemother       Date:  2009-06-01       Impact factor: 5.191

2.  Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing.

Authors:  Delphine Croisier-Bertin; Lionel Piroth; Pierre-Emmanuel Charles; Aurélie Larribeau; Donald Biek; Yigong Ge; Pascal Chavanet
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

3.  Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance.

Authors:  H-G Wetzstein
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

4.  In Vitro Resistance Selection in Shigella flexneri by Azithromycin, Ceftriaxone, Ciprofloxacin, Levofloxacin, and Moxifloxacin.

Authors:  George P Allen; Kayla A Harris
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

5.  Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.

Authors:  Aurélie Fillion; Alexandra Aubry; Florence Brossier; Aurélie Chauffour; Vincent Jarlier; Nicolas Veziris
Journal:  Antimicrob Agents Chemother       Date:  2013-07-08       Impact factor: 5.191

6.  Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae.

Authors:  Kelli Metzler; Karl Drlica; Joseph M Blondeau
Journal:  J Antimicrob Chemother       Date:  2012-11-20       Impact factor: 5.790

Review 7.  Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy.

Authors:  Benjamin J Epstein; John G Gums
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations.

Authors:  Alexander A Firsov; Elena N Strukova; Darya S Shlykova; Yury A Portnoy; Varvara K Kozyreva; Mikhail V Edelstein; Svetlana A Dovzhenko; Mikhail B Kobrin; Stephen H Zinner
Journal:  Antimicrob Agents Chemother       Date:  2013-07-29       Impact factor: 5.191

9.  Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models.

Authors:  Elena N Strukova; Yury A Portnoy; Andrey V Romanov; Mikhail V Edelstein; Stephen H Zinner; Alexander A Firsov
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

10.  CD101: a novel long-acting echinocandin.

Authors:  Yanan Zhao; Winder B Perez; Cristina Jiménez-Ortigosa; Grayson Hough; Jeffrey B Locke; Voon Ong; Ken Bartizal; David S Perlin
Journal:  Cell Microbiol       Date:  2016-07-22       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.